A recent study by Asthma + Lung UK has unveiled a concerning increase in emergency department visits due to respiratory conditions like asthma. Established in January 2020, this UK-based charity focuses on improving respiratory health through initiatives targeting asthma and lung diseases. The findings indicate that over 42,000 patients sought emergency care during the 2023/24 period after multiple visits within the last year, marking a rise of nearly 23% compared to the previous year. In response, Bedfont® Scientific Limited, a global leader in breath analysis, advocates for the broader implementation of Fractional exhaled Nitric Oxide (FeNO) testing as a means to enhance asthma management and curtail avoidable hospital admissions.
According to updated recommendations from prominent organizations such as the National Institute of Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN), FeNO testing is now encouraged for adult asthma management. This non-invasive diagnostic tool allows healthcare providers to monitor airway inflammation, a common issue in asthma sufferers. By incorporating FeNO assessments into routine asthma evaluations, medical professionals can assess patient adherence to prescribed treatments and fine-tune therapeutic strategies accordingly. This approach not only improves overall asthma control but also diminishes the necessity for emergency interventions.
Furthermore, a survey conducted by Asthma + Lung UK involving 3,428 participants revealed that nearly half of respondents did not receive follow-up appointments for their condition. The latest guidelines emphasize the importance of conducting regular follow-ups and annual reviews for individuals who have required emergency care. Current NHS statistics highlight an alarming trend where asthma patients frequently revisit hospitals without obtaining the necessary subsequent care. To address this gap, FeNO testing offers early and precise insights into airway inflammation, ensuring timely and appropriate treatment plans for patients.
Jason Smith, CEO of Bedfont®, stresses the urgency of prioritizing lung health within the forthcoming 10-year health strategy. He suggests that increased investment in FeNO testing at primary care levels could significantly reduce asthma-related hospitalizations. Bedfont® remains committed to advancing respiratory health via cutting-edge technology. Their NObreath® FeNO device aids healthcare providers in both diagnosing and managing asthma effectively, thereby minimizing exacerbations and unnecessary hospital visits.
To combat the rising incidence of asthma-related hospital admissions, there is a pressing need for collaborative efforts between healthcare providers, policymakers, and technological innovators. By integrating advanced diagnostic tools such as FeNO testing into standard care practices, it is possible to enhance patient outcomes and alleviate the burden on emergency services. Such measures are crucial steps toward fostering a more robust and responsive healthcare system for respiratory conditions.